MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.37
+0.36
+3.22%
Closed 16:00 11/27 EST
OPEN
10.91
PREV CLOSE
11.02
HIGH
11.73
LOW
10.62
VOLUME
78.31K
TURNOVER
--
52 WEEK HIGH
13.09
52 WEEK LOW
5.47
MARKET CAP
348.48M
P/E (TTM)
-4.4159
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Concert Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Concert Pharmaceuticals, Inc.
ACCESSWIRE · 11/05 11:30
Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients
Benzinga · 11/03 12:02
If You Had Bought Concert Pharmaceuticals (NASDAQ:CNCE) Stock A Year Ago, You Could Pocket A 59% Gain Today
The Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) share price has had a bad week, falling 13%. While that might be a...
Simply Wall St. · 11/01 13:57
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
Concert presented initial data from an ongoing long-term, open-label extension study of CTP-543 in patients with alopecia areata at EADV.
Business Wire · 10/29 15:00
Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
Concert will host a conference call and webcast on November 5, at 8:30 AM to discuss third quarter financial results and provide a business update.
Business Wire · 10/29 12:00
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 10/25 18:42
Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness.
Business Wire · 10/22 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CNCE. Analyze the recent business situations of Concert Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNCE stock price target is 23.80 with a high estimate of 30.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 140
Institutional Holdings: 24.61M
% Owned: 80.30%
Shares Outstanding: 30.65M
TypeInstitutionsShares
Increased
21
899.63K
New
17
437.92K
Decreased
43
1.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Co-Founder/Independent Director
Richard Aldrich
President/Chief Executive Officer/Co-Founder/Director
Roger Tung
Chief Financial Officer/Chief Accounting Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Other
James Cassella
Other
James Cassella,
Secretary
Jeffrey Munsie
Independent Director
Thomas Auchincloss
Independent Director
Ronald Barrett
Independent Director
Jesper Hoiland
Independent Director
Peter Hutt
Independent Director
Wilfred Jaeger
Independent Director
Christine van Heek
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CNCE
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.